Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
Janux Therapeutics Inc (NASDAQ: JANX) closed the day trading at $34.69 down -0.14% from the previous closing price of $34.74. In other words, the price has decreased by -$0.14 from its previous closing price. On the day, 1.68 million shares were traded. JANX stock price reached its highest trading level at $35.25 during the session, while it also had its lowest trading level at $33.2.
Ratios:
For a better understanding of JANX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 35.86 and its Current Ratio is at 35.86. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On September 17, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $47.
On September 10, 2025, Truist started tracking the stock assigning a Buy rating and target price of $100.Truist initiated its Buy rating on September 10, 2025, with a $100 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 14 ’25 when Meyer Andrew Hollman sold 3,333 shares for $30.00 per share. The transaction valued at 99,990 led to the insider holds 84,974 shares of the business.
ANDREW MEYER bought 3,333 shares of JANX for $91,524 on Nov 14 ’25. On Oct 28 ’25, another insider, Meyer Andrew Hollman, who serves as the Chief Business Officer of the company, sold 16,665 shares for $30.06 each. As a result, the insider received 500,987 and left with 82,139 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 2086527360 and an Enterprise Value of 1120194432. For the stock, the TTM Price-to-Sale (P/S) ratio is 208.65 while its Price-to-Book (P/B) ratio in mrq is 2.14. Its current Enterprise Value per Revenue stands at 112.019 whereas that against EBITDA is -7.877.
Stock Price History:
The Beta on a monthly basis for JANX is 2.79, which has changed by -0.23269188 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, JANX has reached a high of $71.71, while it has fallen to a 52-week low of $21.73. The 50-Day Moving Average of the stock is 30.13%, while the 200-Day Moving Average is calculated to be 29.04%.
Shares Statistics:
Over the past 3-months, JANX traded about 947.70K shares per day on average, while over the past 10 days, JANX traded about 1146810 shares per day. A total of 60.12M shares are outstanding, with a floating share count of 53.79M. Insiders hold about 10.56% of the company’s shares, while institutions hold 107.10% stake in the company. Shares short for JANX as of 1763078400 were 7131951 with a Short Ratio of 7.53, compared to 1760486400 on 8562496. Therefore, it implies a Short% of Shares Outstanding of 7131951 and a Short% of Float of 17.03.
Earnings Estimates
Investors are keenly observing as 12.0 analysts analyze and rate. The current performance of Janux Therapeutics Inc (JANX) in the stock market.The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.56 and low estimates of -$1.06.
Analysts are recommending an EPS of between -$1.28 and -$2.56 for the fiscal current year, implying an average EPS of -$1.98. EPS for the following year is -$2.98, with 13.0 analysts recommending between -$2.38 and -$4.6.
Revenue Estimates
A total of 14 analysts have provided revenue estimates for JANX’s current fiscal year. The highest revenue estimate was $11M, while the lowest revenue estimate was $10M, resulting in an average revenue estimate of $10.07M. In the same quarter a year ago, actual revenue was $10.59M
